Date:2/25/2010

onstrate our solutions using the kind of clinical scenarios our customers face every day."

B. Braun will demonstrate the Outlook ® Safety Infusion System, DoseTrac™ and DoseLink

(B. Braun's IHE compliant HL7 interfaces) systems and its medication administration and electronic health record interoperability at the Healthcare Information and Management Systems Society's HIMSS10 Interoperability Showcase at booth 233 in the Atlanta Convention Center during the HIMSS Conference & Exhibition, March 1-4 in Atlanta.

Designed as a HIMSS Health Information Exchange (HIE)-based environment, the Showcase includes clinical scenarios enabled by the standards-based IHE technical framework and HITSP federally-recognized Interoperability Specifications.

B. Braun will demonstrate the interoperability of its DoseTrac
'/>"/>

SOURCE B. Braun Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. MEDRAD and B. Braun Melsungen AG Collaborate to Promote Breakthrough Medical Treatment for Cardiovascular Disease
2. B. Braun Introduces WHIN(R) Safe Huber Needle
3. B. Braun and Amerinet Sign to Expand Infusion Therapy Offerings
4. B. Braun Awarded Contract With HealthTrust Purchasing Group to Provide Pain Management Solutions
5. B. Braun Medical Inc. to Demonstrate Infusion Systems Technologies at HIMSS 2009 Interoperability Showcase
6. I3, the Developer of Innovative Infusion Therapy Solutions, to Present at Medtech Insight In3 Conference in Las Vegas, March 4-5, 2010
7. Healthcare Industry Celebrates 25 Years of Advanced Pain Management With PCA Infusion System
8. Worlds First Cardiac Adult Stem Cell Patient Receives Infusion
9. Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series
10. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
11. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)